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A B S T R A C T
Background
Long-acting muscarinic antagonists (LAMA), a class of drugs with proven effectiveness in chronic obstructive pulmonary disease
(COPD), are being considered as an add-on option for adults with asthma whose condition is uncontrolled on inhaled corticosteroids
(ICS). It is important to assess the safety and efﬁcacy of LAMA add-on as an alternative to the prolonged use of higher doses of ICS,
which are known to cause undesirable side effects in some people.
Objectives
To compare the effects of adding a LAMA to any dose of ICS versus increasing the dose of ICS, for uncontrolled asthma in adults.
Search methods
We searched the Cochrane Airways Group Specialised Register (CAGR) from its inception in 1995 to April 2015, imposing no
restriction on language of publication. We also handsearched trial registries, reference lists of primary studies and existing reviews, as
well as manufacturers’ websites.
Selection criteria
We looked for parallel or cross-over randomised controlled trials lasting at least 12 weeks, in which adults whose asthma was not
well controlled on ICS alone were randomised to treatment with LAMA add-on to ICS or with an increased dose of ICS. Trials were
excluded if patients were taking long-acting beta2-agonists during the study period.
Data collection and analysis
Two review authors independently screened the searches and extracted data from studies meeting all the inclusion criteria. We used
Covidence to manage duplicate screening, data extraction and risk of bias judgements, and to form a consensus where discrepancies
arose. We used standard methods expected by The Cochrane Collaboration.
The pre-speciﬁed primary outcomes were exacerbations requiring a course of oral corticosteroids (OCS), effects on quality of life and
serious adverse events.
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Main results
One cross-over randomised controlled trial met the inclusion criteria. The trial was performed in 210 patients with moderate to severe
asthma and compared the use of the LAMA tiotropium bromide with double dose beclomethasone (an ICS) using a cross-over design
and 14-week treatment periods.
Compared with people taking a double dose of ICS, fewer people taking a LAMA add-on had an exacerbation requiring treatment
with OCS (odds ratio (OR) 0.57, 95% conﬁdence interval (CI) 0.22 to 1.43) or an exacerbation resulting in emergency department
admission (OR 0.49, 95% CI 0.09 to 2.77), but the conﬁdence intervals for both outcomes did not exclude the possibility that double
dose ICS was more effective. Serious adverse events and exacerbations requiring hospitalisation occurred in similarly low numbers of
people taking each treatment, but conﬁdence intervals were too wide to suggest that the two treatment options were equivalent.
Asthma-related quality of life was similar in both treatment groups (mean difference (MD) in change from baseline 0.10, 95% CI −
0.07 to 0.27). Those taking LAMA add-on scored slightly better on a scale measuring asthma control than those increasing their ICS
dose (MD in change from baseline − 0.18, 95% CI − 0.34 to − 0.02), although the difference was clinically small. Evidence was
deemed low quality for both quality of life and asthma control.
There was moderate-quality evidence that participants’ trough forced expiratory volume in one second (FEV1) was 100 mL better
when taking LAMA add-on than with increased ICS dose (MD in change from baseline 0.10, 95% CI 0.03 to 0.17).
Authors’ conclusions
Only one randomised trial was found, comparing tiotropium add-on to increased dose beclomethasone. Differences between the
treatments were too small or imprecise to understand whether adding a LAMA to ICS is safer or more effective than increasing the dose
of ICS, and there is a possibility of carry-over effects due to the study’s cross-over design. LAMA add-on may lead to more improvement
in lung function (FEV1) than an increased dose of ICS.
The results of this review, alongside pending results from related reviews assessing the use of LAMA against other treatments, will help
to deﬁne the role of these drugs in asthma management, and this review should be updated as results from future trials emerge. Studies
assessing the role of LAMA add-on should be longer and include a double-ICS treatment arm so that the results can be interpreted in
the context of the guideline-recommended treatment options that are available to physicians.
P L A I N L A N G U A G E S U M M A R Y
For people with uncontrolled asthma on inhaled steroids, is it better to increase the dose or add a long-acting muscarinic
antagonist?
We don’t yet know whether adding LAMA to ICS is better or worse than increasing the dose of ICS. It is important that future studies
include a treatment group for people given a double dose of ICS, because this is an option for doctors treating people with asthma.
Why is the question important?
Physicians treating patients with asthma that is not adequately controlled by inhaled corticosteroids (ICS) can either increase the dose of
steroids or add another type of treatment. One type of drug that can complement ICS are long-acting muscarinic antagonists (LAMAs),
which are effective in treating other lung diseases and are starting to become available for treating asthma. Increasing the dose of ICS
can cause unwanted side effects such as weakened bones, sleep problems and anxiety, so adding a LAMA to existing doses of ICS may
be an effective alternative.
How did we answer the question?
Two people looked for published and unpublished research in several databases and websites to ﬁnd relevant studies comparing LAMA
plus ICS with increased doses of ICS for asthma in adults. We analysed the results available up to April 2015 in this systematic review.
What did we find?
We found one study involving 210 patients with asthma. The trial compared adding tiotropium (a LAMA) to doubling the dose of
beclomethasone (a steroid).
In the trial, people taking a combination of the LAMA and ICS were slightly less likely to have an asthma attack needing treatment
with oral steroids. Our results suggest that for every 1000 people, 18 fewer in the LAMA group would need these treatments compared
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to patients treated with an increased dose of ICS. However, there is a relatively wide margin of error in this estimate, and the actual
number of patients on LAMA who might need steroids because of an asthma attack could range from 52 fewer to 26 more people per
1000. Similarly, neither option was more clearly beneﬁcial on any of the following measures: asthma attacks resulting in hospitalisation
or admission to the emergency department, serious adverse events, control of asthma or quality of life related to asthma. On the other
hand, LAMA plus ICS might improve lung function a bit more than increasing ICS dose.
We didn’t have much conﬁdence in the ﬁndings because the one included study only looked at one type of LAMA (tiotropium) for a
short period of time (14 weeks).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
ICS + LAM A add-on versus ICS dose increase for adults with asthma
Patient or population: adults with asthma
Settings: outpat ient
Intervention: ICS + LAMA add-on
Comparison: ICS dose increase
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ICS dose increase ICS + LAM A add-on
Exacerbat ions requir-
ing a course of OCSa
14 weeks
68 per 1000b 40 per 1000
(16 to 94)
OR 0.57
(0.22 to 1.43)
174
(1 RCT)
⊕⊕©©
low c,d
No clear benef it of
one treatment over the
other
AQLQ score
(Scale 1 to 7, where 1 =
severely impaired and 7
= no impairment)
14 weeks
The mean change f rom
baseline in the ICS
dose-increase group
was 0.15e
The mean change f rom
baseline was 0.1 bet-
ter in the LAMA add-on
group (0.07 worse to 0.
27 better)
- (1 RCT) ⊕⊕©©
lowc,f
No clear benef it of
one treatment over the
other;
MCID for AQLQ is 0.5
SAEs (all cause)
14 weeks
17 per 1000b 17 per 1000
(3 to 81)
OR 1.00
(0.20 to 5.09)
174
(1 RCT)
⊕⊕©©
lowc,d
No clear benef it of
one treatment over the
other
Exacerbat ions requir-
ing hospitalisat ion
14 weeks
6 per 1000b 6 per 1000
(0 to 84)
OR 1.00
(0.06 to 16.24)
174
(1 RCT)
⊕⊕©©
lowc,d
No clear benef it of
one treatment over the
other
Exacerbat ions requir-
ing ED visit
14 weeks
23 per 1000b 11 per 1000
(2 to 60)
OR 0.49
(0.09 to 2.77)
174
(1 RCT)
⊕⊕©©
lowc,d
No clear benef it of
one treatment over the
other
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FEV1 pre-albuterol (L) The change f rom base-
line in the ICS dose-in-
crease group was 0.02
Le
The mean change f rom
baseline was 0.1 L bet-
ter in the LAMA add-on
group (0.03 better to 0.
17 better)
- (1 RCT) ⊕⊕⊕©
moderatec
Some benef it of LAMA
add-on versus ICS dose
increase; MCID not well
established
ACQ score
Scale = 0 to 6 (0 = no im-
pairment; 6 = maximum
impairment)
14 weeks
The change f rom base-
line in the ICS dose-in-
crease group was − 0.
03e
The mean dif ference
in change f rom base-
line was − 0.18 in the
LAMA add-on group (0.
34 worse to 0.02 worse)
- (1 RCT) ⊕⊕©©
lowc,f
Small benef it of LAMA
add-on over ICS dose
increase; unlikely to
be clinically signif icant
(MCID = 0.5)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ACQ: Asthma Control Quest ionnaire; AQLQ: Asthma Quality of Life Quest ionnaire; CI: Conf idence interval; ED: emergency department; FEV1 : f orced expiratory volume in one
second; ICS: inhaled cort icosteroids; LAM A: long-act ing muscarinic antagonist ; M CID: m inimal clinically important dif f erence; OCS: oral cort icosteroids; OR: odds rat io; RCT :
randomised controlled trial; SAE: serious adverse event.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aAnalyses included one part icipant who received systemic intravenous cort icosteroids only.
bAssumed risk for dichotomous outcomes was based on the mean number of endpoint events in the ICS dose increase group
(addit ional data provided by authors).
cThe included study only examined one drug (t iotropium) in the LAMA class, and compared it with only one type of ICS
(beclomethasone). Therefore, we cannot be certain how this evidence relates to other LAMA and ICS drugs. Furthermore,
the durat ion of each treatment period in the single included study was only 14 weeks. Therefore, this lim its the likelihood
of detect ing rare events such as exacerbat ions and serious adverse events (i.e. the dichotomous outcomes). Overall, each
outcome was downgraded one point for indirectness [− 1 indirectness].
dConf idence intervals are wide; analysis included data f rom only one study [− 1 imprecision].
eAssumed risk for cont inuous outcomes was based on the mean change f rom baseline in the ICS dose increase group (see
table 2 in Peters 2010).
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f The washout period between treatments in the included study may have been insuf f icient. There was some carryover ef fect
between treatment periods relat ing to the number of asthma control days (this could inf luence a pat ients percept ion of
asthma control and quality of lif e).
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B A C K G R O U N D
Description of the condition
Asthma is a “common and potentially serious chronic disease”
that causes difﬁculty breathing due to narrowing of the airways,
thickening of the airway walls and increased mucus production
(GINA 2014). Asthma is recognised as a heterogeneous disease,
but common symptoms include “wheezing, shortness of breath,
chest tightness and cough that vary over time in their occurrence,
frequency and intensity” (GINA 2014).
Around the world and particularly in low- and middle-income
countries, asthma is frequently undiagnosed anduntreated (Global
Asthma Report 2014), and it remains a signiﬁcant cause of avoid-
able morbidity and mortality in developed countries such as the
UK (NRAD 2014), imposing “a substantial burden on patients,
their family and the community” (GINA 2014). Recent estimates
suggest 334 million people are affected worldwide, with among
the highest direct treatment costs and indirect costs of lost pro-
ductivity for non-communicable diseases (Global Asthma Report
2014). Prevalence estimates vary, and changes over time have been
linked to various factors including air pollution, tobacco legisla-
tion, diet and prevalence of other atopic diseases (Anderson 2005).
The two broad aims of asthma treatment are to maintain daily
symptom control and prevent acute worsening of symptoms
known as asthma attacks or ’exacerbations’. To achieve this, med-
ication, usually given via an inhaler, is started at the most appro-
priate level based on severity and frequency of symptoms, and
in accordance with treatment ’steps’ laid out in guidelines (e.g.
BTS 2014; GINA 2014). Depending on symptom control and
frequency of exacerbations after treatment has commenced, ther-
apy can be stepped up by increasing dosage or adding medications
to recapture control, or ’stepped down’ to maintain patients at the
lowest effective level of therapy and minimise side effects.
Description of the intervention
The lowest treatment step for asthma in most guidelines is the sole
use of a short-acting bronchodilating inhaler (e.g. salbutamol) on
an as-needed basis, which is often sufﬁcient to treat mild or inter-
mittent symptoms.Regular use of low-dose inhaled corticosteroids
is the primary recommended preventer therapy for people with
persistent asthma that is inadequately controlled with as-needed
medication alone (Step 2, BTS 2014; GINA 2014). Regular ICS
has been shown to improve lung function and reduce the need
for reliever medications (Adams 2008a; Adams 2008b), but some
people will continue to have symptoms and asthma attacks. For
this group of patients, guidelines suggest a range of treatment op-
tions (step 3 and above). Long-acting beta2-agonists (LABA) such
as formoterol and salmeterol are the current preferred add-on ther-
apy at step 3 (Ducharme 2008; GINA 2014), as they have been
shown to have often small but statistically signiﬁcant beneﬁts on a
range of outcomes over other treatment options such as increasing
ICS dose (Ducharme 2010), adding theophylline (Tee 2009), or
adding a leukotriene receptor antagonist (Chauhan 2014). Add-
on drugs that allow the ICS dose to be kept low are often seen
as preferable since prolonged use of higher doses of ICS carries
the risk of serious unwanted effects, including growth retardation
in children, decreased bone density, eye disorders, sleep problems
and anxiety (NICE 2013).
Long-acting muscarinic antagonists (LAMA), a class of drugs
with proven effectiveness in chronic obstructive pulmonary dis-
ease (COPD) (Karner 2014), are now being considered as another
add-on therapy for asthma in adults who require more than ICS
alone. Tiotropium, the ﬁrst and most widely used LAMA to be
licenced for COPD , has demonstrated added beneﬁts over LABA
in terms of the frequency of exacerbations and hospital admis-
sions for COPD, but not in terms of mortality or overall hospi-
tal admissions (Chong 2012). Evidence for the safety and efﬁcacy
of aclidinium bromide and glycopyrronium bromide, two LAMA
formulations that have recently been licensed for use in COPD,
is also emerging (Ni 2014).
How the intervention might work
LAMAs block receptors of the neurotransmitter acetylcholine on
airway smooth muscle, glands and nerves, preventing muscle con-
traction andmucus secretion (Moulton 2011). The actionon these
receptors helps to alleviate symptoms of breathlessness, coughing
and wheezing that characterise asthma (Lipworth 2014). These
characteristics of LAMA, together with the overlap in pathophysi-
ology and symptoms between asthma and COPD (Gosens 2006),
have led to their testing as an add-on therapy for asthma in pa-
tients who do not achieve adequate control from standard-dose
ICS alone. This course of treatment has the potential advantage
of avoiding prolonged exposure to higher doses of ICS.
The most commonly reported side effect of LAMA for airways
disease is dry mouth, with others including constipation, diar-
rhoea, cough and headache (BNF). All LAMAs for maintenance
of airways disease are delivered via inhalers, either by powder
(tiotropium bromide, usually delivered via theHandiHaler device;
aclidinium bromide, via Genuair; glycopyrronium bromide, via
Breezhaler) or soft mist delivery (albuterol and ipratropium com-
bination, via Respimat) and are not suitable to be used as rescue
medication.
In COPD, there is conﬂicting evidence regarding the safety of
tiotropium delivered via the Respimat device, with one recent ob-
servational study ﬁnding it increased the risk of death, particu-
larly cardiac, compared with placebo via the HandiHaler device
(Verhamme 2013). Another large randomised trial including over
17,000 people with COPD found no signiﬁcant differences in
long-term safety between the two devices (Wise 2013). As yet it is
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unclear whether differential safety proﬁles will be seen in people
with asthma.
Why it is important to do this review
Tiotropium bromide (Spiriva Respimat 2.5 mcg) is the only
LAMA preparation that has been granted a UK license for use in
severe asthma in combination with LABA and ICS (eMC 2014).
Following the demonstrated efﬁcacy of LAMAs in COPD (Karner
2014), clinical trials are emerging to test the use of various LAMA
regimens against the existing treatment options for asthma. One
study found that nearly 30% of patients whose asthma was un-
controlled on ﬂuticasone remained so with the guideline-recom-
mended addition of LABA (Bateman 2004), suggesting there is a
need for more options for add-on therapy.
It is important to assess the safety of using LAMA add-on to ICS
as an alternative to prolonged use of high doses of ICS, which
are known to cause undesirable side effects (NICE 2013). As a
complement to results from three other reviews, this review sum-
marises the evidence to guide the possible use of LAMA add-on
as an alternative steroid-sparing agent. The other reviews assess
LAMA add-on compared with LABA add-on (Kew 2015), LAMA
add-on compared with no change to ICS dose (Allison 2014) and
LAMA add-on as part of a triple therapy with LABA+ICS com-
pared with LABA+ICS alone (Kew 2015).
O B J E C T I V E S
To compare the effects of adding a LAMA to any dose of ICS versus
increasing the dose of ICS, for uncontrolled asthma in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included double-blinded parallel or cross-over randomised
controlled trials (RCTs) lasting at least 12 weeks. We included
studies reported as full-text and those published as abstract only, as
well as unpublished data. Because the long-term effects of ICSmay
not wash out between treatments in cross-over trials, we performed
a sensitivity analysis excluding them from the primary analyses.
We did not exclude studies on the basis of a lack of blinding.
Types of participants
We included adults (at least 18 years) whose asthma was not well
controlled on ICS alone. We excluded trials that included partic-
ipants with other chronic respiratory comorbidities (e.g. COPD,
bronchiectasis).
If studies also included adolescents or children under 12, and data
were not reported separately, we included them if the mean age in
both treatment groups was over 18.
Types of interventions
We included studies that randomised participants to receive any
dose of the following LAMA preparations as an add-on to any
dose of ICS.
• Tiotropium (Spiriva Handihaler or Respimat).
• Aclidinium bromide (Eklira Genuair).
• Glycopyrronium bromide (Seebri Breezhaler).
Eligible comparison group participants were randomised to receive
an increase in ICS dose.
We included studies that permitted the use of short-acting med-
ications, such as salbutamol or a combination of terbutaline and
ipratropium, as reliever therapy. However, to assess the effect of
LAMA plus ICS in isolation, we excluded trials where:
• a long-acting beta2-agonist (LABA) was given as part of the
randomised treatment (i.e. LAMA+ICS+LABA vs. ICS+LABA);
• participants were required to be taking a LABA to be
included in the trial; and
• the majority of participants continued treatment with
LABA alongside the randomised treatment.
Types of outcome measures
Primary outcomes
1. Exacerbations requiring oral corticosteroids
2. Quality of life (measured on a validated asthma scale, e.g.
Asthma Quality of Life Questionnaire)
3. Serious adverse events (all causes)
Secondary outcomes
1. Exacerbations requiring hospitalisation
2. Lung function (in particular, trough FEV1)
3. Asthma control (measured on a validated scale, e.g. Asthma
Control Questionnaire or Asthma Control Test)
4. Adverse events
Reporting one or more of the outcomes listed here in the trial was
not an inclusion criterion for the review.
If exacerbations were reported as a composite of more than one
deﬁnition (e.g. patients with one or more exacerbations requiring
hospitalisation or emergency department visit), theywere analysed
separately.
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Search methods for identification of studies
Electronic searches
We identiﬁed trials from the Cochrane Airways Group Specialised
Register (CAGR), which is maintained by the Trials SearchCo-or-
dinator for theGroup.TheRegister contains trial reports identiﬁed
through systematic searches of bibliographic databases including
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, CINAHL, AMED and PsycINFO as well
as through handsearching of respiratory journals and meeting ab-
stracts (please see Appendix 1 for further details). We searched all
records in the CAGR using the search strategy in Appendix 2. The
most recent search was conducted in April 2015.
We also conducted a search
of ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO trials
portal (www.who.int/ictrp/en/). We searched all databases from
their inception to the present, with no restriction on language of
publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We also searched relevant man-
ufacturers’ websites for trial information.
A search was performed on 19 Feburary 2015 for errata or re-
tractions from included full-text studies published on PubMed
(www.ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
Selection of studies
The titles and abstracts of all potential studies identiﬁed by the
search were independently screened for inclusion by two review
authors (KK and DE, using Covidence) and coded as ’retrieve’
(eligible or potentially eligible/unclear) or ’do not retrieve’. We
retrieved the full-text study reports and publications, and two re-
view authors independently screened these to identify studies for
inclusion or to identify and record reasons for the exclusion of
the ineligible studies. We resolved any disagreement through dis-
cussion, or if required, we consulted a third person (DA or AB).
Duplicates were identiﬁed and excluded, and multiple reports of
the same study were collated so that each study (rather than each
report) was the unit of interest in the review. The selection pro-
cess was recorded in sufﬁcient detail to complete a PRISMA ﬂow
diagram and ’Characteristics of included studies’ table.
Data extraction and management
We used a data collection form for study characteristics and out-
come data, which had been piloted on a related systematic review.
Two review authors (DE and KK) extracted the following charac-
teristics from the included study.
1. Methods: study design, total duration of study, details of
any run-in period, number of study centres and location, study
setting, withdrawals and study period.
2. Participants: Number of patients, mean age, age range, sex,
severity and duration of condition, diagnostic criteria, baseline
lung function, smoking history, inclusion criteria and exclusion
criteria.
3. Interventions: intervention, duration of intervention,
comparison, concomitant medications and excluded
medications.
4. Outcomes: primary and secondary outcomes speciﬁed and
collected, and time points reported.
5. Notes: funding for trial and notable conﬂicts of interest of
trial authors.
Two review authors (KK and DE) independently extracted
outcome data from the included study. We noted in the ’
Characteristics of included studies’ table if outcome data were not
reported in a usable way. Disagreements were resolved by consen-
sus or by involving a third person (DA or AB). One review author
(DE) transferred the data into the RevMan ﬁle and another author
double-checked that data were entered correctly by comparing the
data presented in the systematic reviewwith the study report (KK).
Assessment of risk of bias in included studies
Two review authors (DE and KK) independently assessed the risk
of bias for the study using criteria outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
resolved any disagreements by discussion or by involving another
author (DA or AB). The risk of bias was assessed according to the
following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low or unclear and
provided a quotation from the study report together with a justi-
ﬁcation for our judgment in the ’Risk of bias’ table. We planned
to summarise the risk of bias judgements across different studies
for each of the domains listed, but there was only one included
study. We considered blinding separately for different key out-
comes where necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different than for
a patient-reported pain scale). Where information on risk of bias
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related to unpublished data or correspondence with a trialist, we
noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
We conducted the review according to the published protocol and
reported any deviations in the ’Differences between protocol and
review’ section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios (ORs) and continu-
ous data as mean difference (MD) or standardised mean difference
(SMD). Data presented as a scale were entered with a consistent
direction of effect. We provided a narrative description of skewed
data reported as medians and interquartile ranges. We analysed
data from the cross-over trial using generic inverse variance and
only if double-counting of participants was accounted for. If raw
data and adjusted analyses (e.g. accounting for baseline differences)
were both presented, we used the latter.
If more studies are identiﬁed in future updates of this review,
we will perform meta-analyses only where meaningful (i.e. if the
treatments, participants and the underlying clinical question are
similar enough for pooling to make sense).
Where multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) were combined in the
same meta-analysis, we halved the control group to avoid double-
counting.
If change frombaseline and endpoint scores were available for con-
tinuous data, we used the change from baseline unless themajority
of studies reported endpoint scores. If a study reported outcomes
at multiple time-points, we used the end-of-study measurement.
When an analysis using only participants who completed the trial
and an analysis which imputed data for participants who were ran-
domised but did not provide endpoint data (e.g. last observation
carried forward) were both available, we used the latter.
For dichotomous outcomes, we assumed equivalence of treatments
if the odds ratio estimate and its 95% conﬁdence intervals were
between the pre-deﬁned arbitrary limits of 0.9 and 1.1.
Unit of analysis issues
For dichotomous outcomes, we used participants rather than
events as the unit of analysis (i.e. number of adults admitted to
hospital rather than number of admissions per adult). However,
if exacerbations were reported as rate ratios we analysed them
on this basis. For cross-over trials, we requested data in the for-
mat described in Elbourne 2002 to control for intercorrelation of
matched pairs. For continuous data in cross-over trials, we entered
data using generic inverse variance from suitable adjusted analyses
to account for the trial’s design.
Dealing with missing data
Where possible, we contacted investigators or study sponsors to
verify key study characteristics and obtain missing numerical out-
come data (e.g. when a study is identiﬁed as abstract only). If this
was not possible, and the missing data were thought to introduce
serious bias, we explored the impact of including such studies in
the overall assessment of results using a sensitivity analysis.
Assessment of heterogeneity
We planned to use the I² statistic to measure heterogeneity among
the trials in each analysis, report if substantial heterogeneity was
identiﬁed (e.g. I2 greater than 30%) and explore possible causes
by pre-speciﬁed subgroup analysis.
Assessment of reporting biases
Wewere unable to pool more than 10 trials, so it was not necessary
to use a funnel plot to explore possible small study and publication
biases.
Data synthesis
We planned to use a random-effects model for all analyses, as we
expected variation in effects due to differences in study populations
and methods. We planned to perform sensitivity analyses with a
ﬁxed-effect model. As only one study met the inclusion criteria for
this review, meta-analyses were not performed.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses for the primary out-
comes.
1. Duration of therapy (≤ 6 months, > 6 months).
2. Corticosteroid dose in the control group (according to
GINA 2014 deﬁned low, medium and high cutoffs).
3. Dose and type of LAMA (e.g. tiotropium Handihaler 18
mcg, tiotropium Respimat 5 mcg).
We planned to use the formal test for subgroup interactions in
Review Manager (RevMan).
Sensitivity analysis
We planned to perform sensitivity analyses on the primary out-
comes, excluding the following.
1. Unpublished data.
2. Studies at high risk of bias for blinding of participants and
personnel.
3. Cross-over studies*.
*There may be longer term effects of ICS that do not wash out
before a subsequent treatment is started in cross-over trials, espe-
cially at higher doses.
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Summary of findings table
We created a ’Summary of ﬁndings’ table (Summary of ﬁndings
for the main comparison) to present results for all of the named
outcomes. We used the ﬁve GRADE considerations (study limi-
tations, consistency of effect, imprecision, indirectness and publi-
cation bias) to assess the quality of the evidence as it related to the
data used to analyse the pre-speciﬁed outcomes. We applied meth-
ods and recommendations described in Section 8.5 and Chapter
12 of theCochraneHandbook for Systematic Reviews of Interventions
(Higgins 2011) using GRADEpro software (Brozek 2008), justi-
fying all decisions to downgrade or upgrade the quality of studies
using footnotes and providing comments to aid the reader’s un-
derstanding of the review where necessary.
R E S U L T S
Description of studies
Results of the search
We identiﬁed 58 records in the main electronic database searches,
and 121 other records by searching additional resources (Clinical-
Trials.gov, reference lists of other publications and drug company
websites). Fifty-nine of the total 179 records were duplicates. We
screened the remaining 120, excluding 79 based on the title and
abstract alone. For the remaining 41, we retrieved full texts and
grouped them into 34 studies. After viewing them and resolving
discrepancies, we excluded 33 studies (37 records), leaving one
RCT that met all the inclusion criteria. The reasons for exclusion
can be found below in the Excluded studies section. We did not
identify any ongoing studies, and no studies are awaiting classiﬁ-
cation. Trial ﬂow is presented in Figure 1.
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Figure 1. Study flow diagram
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Included studies
We identiﬁed one study making the comparison of interest that
met the inclusion criteria (Peters 2010).Details of study character-
istics are provided in the ’Characteristics of included studies’ table.
Brieﬂy, 210 adult participants with asthma received tiotropium
bromide (a LAMA) plus beclomethasone (an ICS); salmeterol xi-
naoate (LABA) plus beclomethasone, or double-dose beclometha-
sone, in a randomly assigned order (three-way cross-over design).
Only the LAMA plus ICS and double ICS groups are relevant
to the present review and are considered herein. The comparison
between the LAMA plus ICS and LABA plus ICS groups fea-
tures in a related systematic review (Kew 2015). Participants had
moderate to severe asthma that was inadequately controlled by a
low-dose ICS (low-dose); patients were symptomatic (i.e. required
daily controller therapy).We contacted the authors of the included
study, who were able to provide additional information and anal-
yses.
Design
Peters 2010 was a three-way, double-blind, triple-dummy cross-
over trial in which patients where randomised to the order in
which they received each of the three treatments. The study was
performed at multiple centres in the United States, and total
study duration was one year, comprising a four-week run-in pe-
riod followed by three 14-week treatments periods, and separated
by two-week washout periods. As mentioned above, only two of
the three treatment groups were relevant to this review (see below
in ’Characteristics of included studies’ table), and data from these
treatment groups contributed to the present analyses.
Participants
Inclusion and exclusion criteria are listed in the ’Characteristics
of included studies’ table. Inclusion criteria included an age of at
least 18 years, a history of asthma conﬁrmed by bronchodilator re-
versibility or bronchial hyperresponsiveness, a FEV1 of more than
40% of the predicted value, current non-smoking status (with a
history of 10 pack-years or less) and no requirement for addi-
tional asthma medications. Exclusion criteria included vocal cord
dysfunction, respiratory tract infection, other signiﬁcant medical
illness, lung disease other than asthma, an asthma exacerbation
within the previous four weeks, a history of life-threatening asthma
within the previous ﬁve years and pregnancy or no use of accept-
able birth control methods in women of childbearing potential.
The majority (67%) of participants were female. The mean (stan-
dard deviation, SD) age of participants was 42 (±12) years; mean
body mass index was 31.4 (±8.8) kg/m2 and the mean duration of
asthmawas 26 (±14.1) years.Mean percentage predicted FEV1 be-
fore bronchodilation was 71.5% (±14.9%) at baseline. The mean
(SD) Asthma Control Questionnaire (ACQ) score at baseline was
1.64 (±0.73), which is over the suggested cutoff of 1.50 to be con-
ﬁdent of inadequately controlled asthma (Juniper 2006). Baseline
Asthma Quality of Life Questionnaire (AQLQ) score was 5.43
(±1.05).
Interventions
The relevant treatment comparison in the included study com-
prised tiotropium (SpirivaHandihaler; 18mcg once daily) plus be-
clomethasone (hydroﬂuoroalkane metered-dose inhaler; 80 mcg
twice daily) versus a dose increase of beclomethasone (160 mcg
twice daily; i.e. a double dose of the ICS).
Outcomes
The authors of Peters 2010 provided additional data. Continuous
data (mean difference, 95%CI) and dichotomous data (OR, 95%
CI) were entered as adjusted between-group differences to account
for the trial’s cross-over design (Elbourne 2002), so we analysed
outcomes using the generic inverse variance method (Higgins
2011).
Excluded studies
We excluded 33 studies after viewing full texts. The main reason
for exclusion was use of the wrong comparator (n=21 records),
such as ICS alone (relevant to Allison 2014) or ICS plus LABA
(Kew 2015). Other reasons for study exclusion included the fact
that over 50% of participants were taking LABA (n=11 records),
study duration was too short (i.e. less than 12 weeks; n=3 records)
or the wrong intervention was used (n=1 record). Likewise, one
study was an observational cohort study rather than an RCT(n=
1 record). Excluded studies and reasons for exclusion are listed in
the ’Characteristics of excluded studies’ table.
Risk of bias in included studies
The included study was of a high methodological quality. Where
published and publicly available information was insufﬁcient, the
trial authors were able to clarify the methods used.
Allocation
The included study was rated as at low risk of bias for both al-
location domains. Communication with trial authors (Chinchilli
2015 [pers comm]) conﬁrmed that a statistical software package
was used to generate the random sequence that deﬁned the order
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in which treatments would be given. Speciﬁcally, a Data Coordi-
nating Centre carried out this task and developed a web-based sys-
tem to blind allocation. When a patient had completed screening
and was ready for randomisation, a study coordinator at a clinical
centre entered information into the randomisation module and
was notiﬁed of the appropriate blinded drug packet (prepared by
the network pharmacist) for the eligible patient.
Blinding
The included study had a low risk of bias for both participants
and personnel as well as outcome assessor blinding. The three-
period cross-over studywas designed to be double-blind and triple-
dummy with placebo inhalers to blind each of the drugs in each
period. The clinical trial register (ClinicalTrials.gov) stated that
masking was applicable to subjects, caregivers, investigators and
outcome assessors.
Incomplete outcome data
The included study was rated as having a low risk of attrition bias.
Less than 10% of patients dropped out during each treatment
period. The number of patients withdrawing due to adverse events
was lower during treatment with LAMA add-on (n=7) compared
with a double dose of ICS (n=14).
Selective reporting
The included study was judged to be at low risk of bias for selective
reporting. The outcomes deﬁned in the ClinicalTrials.gov regis-
tration were mostly well reported in the published manuscripts,
with the exception of the secondary biomarker outcomes, which
did not inﬂuence the assessment of safety or efﬁcacy. Asthma ex-
acerbations and serious adverse events were not reported in a way
that could be analysed without potentially double-counting par-
ticipants, but the authors were able to provide the missing data.
Other potential sources of bias
Peters 2010 used a cross-over design, and the washout period be-
tween treatments was two weeks. This may not have been sufﬁ-
cient, as the authors commented that although minimal carryover
effects were observed for measures of lung function, an effect was
seen for asthma control days. We considered this to be a potential
source of bias.
Effects of interventions
See: Summary of findings for the main comparison ICS +
LAMA add-on compared to ICS dose increase for adults with
asthma
Only one study (Peters 2010) met the inclusion criteria for this
review. As such, data from several studies could not be pooled, and
no meta-analyses were performed. As the study followed a cross-
over design, we obtained additional data from the authors to allow
us to calculate between group differences for the dichotomous
outcomes. For each dichotomous outcome, the analyses below
were based on all patients with complete follow-up or who had an
event. The results are described below and presented in Summary
of ﬁndings for the main comparison.
Primary outcomes
Exacerbations requiring oral corticosteroids
Fewer people taking a LAMA add-on had an exacerbation requir-
ing treatment with oral steroids compared with people taking dou-
ble dose ICS (OR 0.57, 95% CI 0.22 to 1.43; Analysis 1.1), but
the conﬁdence intervals did not exclude the possibility that dou-
bling ICS was better. For people taking LAMA, we estimated that
18 fewer people per 1000 would have an exacerbation requiring
steroids, but the conﬁdence intervals ranged from 52 fewer to 26
more people per 1000. The quality of the evidence was rated as
low, having been downgraded once for imprecision due to wide
conﬁdence intervals and once for indirectness, as our evidence was
based on a single study examining only one drug in the LAMA
class, and the study lasted only 14 weeks (the results for tiotropium
may not be representative of the LAMA class as a group, and the
relatively short duration of treatment makes it difﬁcult to inter-
pret the ﬁndings for rare events, such as exacerbations or serious
adverse events, in the context of long-term use in adults).
Quality of life
People treated with LAMA add-on were not found to have a dif-
ferent quality of life compared with those treated with an increased
dose of ICS (MD in change from baseline 0.10, 95% CI − 0.07
to 0.27; Analysis 1.2). The evidence was rated as of low qual-
ity after being downgraded once for indirectness (results may not
be representative of LAMA as a class of drugs) and once due to
risk of bias. We downgraded the evidence based on risk of bias
because the washout period between treatments in the included
study may have been too short. Indeed, a degree of carryover effect
between treatment periods was observed in relation to the num-
ber of asthma control days, and this may have inﬂuenced patients’
perception of quality of life as well as asthma control.
Serious adverse event (all causes)
The conﬁdence intervals were too wide to determine if there was
a difference in the number of people who experienced serious
adverse events (SAEs) whilst taking a LAMA add-on compared
with an increased dose of ICS (OR 1.00, 95% CI 0.20 to 5.09;
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Analysis 1.3). The quality of the evidence was rated as low, having
been downgraded once for imprecision due to wide conﬁdence
intervals (SAEs were rare) and once for indirectness (single study
with one type of LAMA and relatively short treatment duration).
Secondary outcomes
Exacerbations requiring hospitalisation
The conﬁdence intervals were too wide to determine if there was
a difference in the number of people who experienced an exac-
erbation requiring hospitalisation whilst taking a LAMA add-on
versus an increased dose of ICS (OR 1.00, 95% CI 0.06 to 16.24;
Analysis 1.4). The quality of the evidence was rated as low, having
been downgraded once for imprecision due to wide conﬁdence in-
tervals (exacerbations were rare events), and once for indirectness
(results may not be representative of LAMA as a class of drugs, and
the treatment duration in the single included study was relatively
short).
Fewer people taking a LAMA add-on had an exacerbation requir-
ing admission to the emergency department compared with peo-
ple taking double dose ICS (OR 0.49, 0.09 to 2.77; Analysis 1.5).
The conﬁdence intervals for this comparison excluded a signiﬁ-
cant effect: for people taking LAMA, we estimated that 12 fewer
people per 1000 would have an exacerbation requiring admission
to the emergency department, but the conﬁdence intervals ranged
from 21 fewer to 37 more people per 1000. The quality of the
evidence was rated as low for the reasons described in the previous
paragraph.
Lung function
Forced expiratory volume in one second (FEV1)
We pre-speciﬁed this outcome as being our primary measure of
lung function. The mean change from baseline in trough FEV1
(L) was greater in people taking a LAMA-add on compared with
those taking an increased dose of ICS (MD 0.10, 95% CI 0.03 to
0.17; Analysis 1.6).The evidence was rated as of moderate quality
after being downgraded once for indirectness because the results
may not be representative of LAMA as a class of drugs. The post-
albuterol measurement also showed a smaller beneﬁt of LAMA
add-on compared with increasing ICS dose (MD 0.04, 95% CI
0.01 to 0.07; Analysis 1.7).
Peak expiratory flow (PEF)
The mean change from baseline in morning PEF (L/min) was
greater in people taking a LAMA-add on compared with those
taking an increased dose of ICS (MD in change from baseline
25.80, 95% CI 14.40 to 37.20; Analysis 1.8). Similarly, the mean
change from baseline in evening PEF was greater in people taking
a LAMA add-on (MD 35.30, 95% CI 24.60 to 46.00; Analysis
1.9).
Asthma control
Asthma control was found to be slightly improved in people taking
a LAMA add-on compared with those taking an increased dose
of ICS (MD in change from baseline − 0.18, 95% CI − 0.34
to − 0.02; Analysis 1.10). However, the magnitude of the mean
difference between treatment groups (and conﬁdence intervals)
was below the established minimal clinically important difference
(MCID) of 0.5 for the ACQ.The evidence was rated as lowquality
after being downgraded once for indirectness (evidence may not
be representative of LAMA class) and once due to a risk of bias
associated with the study design (see AQLQ above).
Adverse events
The published article (Peters 2010) reports that people taking the
double dose of ICS had a higher number of unscheduled visits for
asthma symptoms and events for which urgent care was needed
compared with people taking a LAMA. We did not obtain addi-
tional data speciﬁcally for this endpoint. However, data relating
to exacerbations and serious adverse events are provided above.
D I S C U S S I O N
Summary of main results
One cross-over trial met the inclusion criteria for this review. The
trial was performed in 210 patients withmoderate to severe asthma
and compared the use of beclomethasone 80 mcg twice daily plus
tiotropium bromide 18 mcg once daily (morning) with double
dose (160 mcg) beclomethasone twice daily (Peters 2010). The
study was of good methodological quality and considered to be at
low risk of bias for all domains except one.
Fewer people taking a LAMA add-on had an exacerbation requir-
ing treatment with oral steroids compared with people taking dou-
ble dose ICS, but the conﬁdence intervals did not exclude the pos-
sibility that increased ICS dose was better: our results suggest that
18 fewer people per 1000 taking a LAMA would have an exac-
erbation requiring a course of OCS, but the conﬁdence intervals
ranged from 52 fewer to 26 more per 1000. Approximately equal
numbers of people taking each treatment had an exacerbation re-
quiring hospitalisation, but conﬁdence intervals were too wide to
suggest equivalence. Fewer people taking a LAMA had an exac-
erbation resulting in admission to an emergency department, but
again the conﬁdence intervals did not exclude beneﬁt of an ICS
dose increase. Being based on only a small number of events in
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a single study, the quality of evidence for all of the exacerbation-
related outcomes was rated as low. We downgraded the evidence
based on imprecision and indirectness. Serious adverse events (all
causes) also occurred in similarly low numbers of people taking
each treatment, but the conﬁdence intervals were too wide to con-
clude equivalence. Again, the evidence was downgraded to low
quality due to imprecision and indirectness.
We did not ﬁnd a signiﬁcant difference in asthma-related quality
of life between treatment groups. People taking a LAMA-add on
scored slightly better on a scale measuring asthma control (ACQ)
compared with people taking an increased dose of ICS. The mag-
nitude of this effect was too small to be considered clinically signif-
icant, and the evidence for both of these measures (quality of life
and asthma control) was considered as low quality, having been
downgraded once for imprecision and once for risk of bias.
There was some evidence to support beneﬁts of a LAMA add-on
on lung function over an increased dose of ICS (as assessed by
trough FEV1, our prespeciﬁed measure for lung function). The
quality of evidence for trough FEV1 was rated as moderate, having
been downgraded once for indirectness. Other measures of lung
function (post-bronchodilator FEV1, morning PEF and evening
PEF) also showed a beneﬁt of LAMA add-on. The quality of evi-
dence for these other measures was not assessed, as they were not
pre-speciﬁed as outcomes of interest in the review protocol.
Overall completeness and applicability of
evidence
The current evidence base to address our research question is in-
sufﬁcient in several respects. Only one study was identiﬁed that
met the inclusion criteria for this review, and no sub-group anal-
yses were performed. The single included study used tiotropium
delivered by Handihaler, so we cannot determine if our ﬁnd-
ings are applicable to other LAMA drugs such as glycopyrro-
nium or aclidinium. Likewise, as the included study compared
LAMA with an increased dose of beclomethasone, we cannot de-
termine if the ﬁndings are relevant to other ICS. Several other
studies of LAMA add-on have been completed or published
(NCT01172808; Rajanandh 2014a), but double-dose ICS was
not included as a comparison group, meaning that these studies
are not fully representative of the guideline-recommended treat-
ment options available to clinicians (BTS 2014; GINA 2014).
The included study (Peters 2010) used a cross-over design inwhich
210 participants were randomly assigned to the order in which
they received three treatments, each for 14 weeks (only two treat-
ment periods were relevant to this review). The duration of the
washout periods between treatment regimens was relatively short
(14 days). Studies in patients with asthma have shown that ICS
can have prolonged effects (Haahtela 1994; Juniper 1991) for up
to several weeks after treatment cessation (De Blic 1996). Thus, in
the cross-over study reported by Peters and colleagues, carryover
effects could have confounded the results from the tiotropium
treatment period if patients were randomised to receive the higher
dose of ICS ﬁrst. Indeed, a degree of carryover effect appeared to
affect the results relating to the number of asthma control days
and could have had an impact on the magnitude of difference
for the other outcomes we assessed. The duration of treatment in
the included study was also relatively short. Therefore, we would
urge a cautious interpretation of our ﬁndings in the context of
the medium- to long-term use of LAMA plus ICS, particularly in
terms of safety.
The use of LAMA for asthma is relatively new, with only one UK
licence extension for Spiriva Respimat to be used in combination
with LABA plus ICS for patients with asthma. We anticipate that
the evidence base for this topic will grow as more products are
approved for this indication. Thus, we hope that the applicability
of ﬁndings from future versions of this review will broaden.
Quality of the evidence
The quality of the evidence relating to two of our primary out-
comes, exacerbations and serious adverse events, was rated as low.
This was because only one study was included in this review and
therefore the evidence is based on ﬁndings for only one member
of the LAMA class (tiotropium) and may not be representative of
the class as a whole. Additionally, the duration of each treatment
period in the included study was only 14 weeks, so the evidence
relating to exacerbations and serious adverse events (i.e. relatively
rare events) cannot be considered representative of the long-term
use of these drugs.
The quality of evidence for quality of life and asthma control was
also considered to be low, having beendowngraded for indirectness
and also risk of bias due to evidence of a carryover effect between
treatment periods in the included study, which used a cross-over
design.
The evidence for lung function (using trough FEV1) was graded
as moderate. This decision was based on a single downgrade for
indirectness as discussed above. Notably, the data were extracted
from a cross-over trial where each participant acted as their own
control, hence increasing the power of the study relative to a study
of parallel design and similar size. Although we pre-speciﬁed FEV1
as the primary measure of lung function, other measures of lung
function (PEF and post-bronchodilator FEV1) were not pre-spec-
iﬁed and consequently not assessed for quality of evidence. The
lack of well-established, minimally important differences for lung
function measures made it difﬁcult to interpret the clinical signif-
icance of the magnitude and precision of the difference between
LAMA add-on and increased dose ICS. A change of approximately
10% from baseline in FEV1 was reported as theMCID for asthma
patients, although this was based on patient perception of change
and is not well established (Reddel 2009). Using this threshold
in relation to the participants’ baseline pre-albuterol FEV1, 100
mL would not be considered clinically important, but changes in
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morning and evening PEF were above a reportedMCID of 18.8L/
min (Reddel 2009).
Potential biases in the review process
The review was conducted to the standards set by MECIR 2013
and in accordance with the published protocol (Kew 2014). There
were several deviations from the protocol (see Differences between
protocol and review), the majority of which arose due to the in-
clusion of a single study in the review.
It is unlikely that any relevant studies were missed, as a skilled
information specialist conducted the main electronic searches.
Additionally, the main searches were supplemented by extensive
searches of several other sources (pharmaceutical company clinical
trial registries and reference lists of associated studies and reviews)
in addition to those required by MECIR 2013 (i.e. ClinicalTri-
als.gov, WHO trials portal). We also contacted the authors of the
included study, who provided all requested additional or missing
data and study information that was not available in the published
report.
Agreements and disagreements with other
studies or reviews
Several other systematic reviews have considered the use of LAMA
for asthma (Befakadu 2014; Rashid 2014; Rodrigo 2015) but only
Befakadu compared the LAMAversus increased dose of ICS (with-
out LABA). Their narrative synthesis for the LAMAversus double-
ICS comparison was also based on the single study by Peters 2010.
The authors noted that tiotropium was superior to doubling the
dose of ICS, but this was based on the primary outcome of the
study, morning peak expiratory ﬂow, which we did not consider
as the primary measure of lung function in this review. Befakadu
and colleagues also noted evidence of improved lung function in
patients taking LAMA plus ICS compared with those taking in-
creased doses of ICS; the authors concluded that it remains to be
seen whether the lung function improvements will result in long-
term symptom improvement. These ﬁndings are generally in line
with those of this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Only one randomised trial was found, comparing tiotropium add-
on to increased dose beclomethasone. Differences between the
treatments were generally too small or imprecise to tell whether
adding a LAMA to ICS is safer or more effective than increasing
the dose of ICS, and there is a possibility of carryover effects due
to the study’s cross-over design. LAMA add-on may lead to more
improvement in lung function (FEV1) than increasing ICS dose.
Implications for research
The results of this review, alongside pending results from related
reviews assessing the use of LAMA against other treatments, will
help to deﬁne the role of these drugs in asthma and should be
updated as results from future trials emerge. Studies assessing the
role of LAMA add-on should be longer and include a double-
ICS treatment arm so that the results can be interpreted in the
context of the guideline-recommended treatment options that are
available to physicians.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Peters 2010
Methods Study design: RCT
Study grouping: cross-over
Open Label: NO
Cluster RCT: NO
Participants Baseline Characteristics: For the whole population, patients received the treatments in
a random sequence with washout
• Setting: 10 university medical centres; outpatient services.
• Country: USA.
• Mean age in years (SD): 42.2 (±12.3)
• % male: 32.9
• % white: 54.8
• FEV1 (% predicted (SD)): 71.5 (±14.9)
• Duration of asthma in years (SD): 26.1 (±14.1)
• Number randomised: 210
• Number completed: 174
Inclusion criteria: at least 18 years of age; clinical history consistent with asthma; FEV1
> 40% predicted value; asthma conﬁrmed by beta-agonist reversibility to four puffs
albuterol of ≥ 12%; OR methacholine provocative concentration at 20% (PC20) of ≤
8 mg/mL (not on ICS), or ≥ 16 mg/mL (on ICS); need for daily controller therapy
(i.e. ICS, leukotriene modiﬁers, long-acting beta-agonists, or a combination of these);
received prescription for or used asthma controller in previous 12months;OR symptoms
> twice a week and not on asthma controller; if on ICS, stable dose for at least two weeks
not exceeding 1000 mcg ﬂuticasone or equivalent daily; non-smoker for at least one year
and total lifetime history < 10 pack-years; if female of child-bearing potential, willing
to use an effective form of birth control throughout the study; able to measure morning
PEF on schedule using meter and to complete the study diary correctly at least 75% of
the time during week 2 to 4 run-in interval; ≥ 75% adherence with study medication
during run-in; no asthma exacerbation requiring oral corticosteroids or additional asthma
medications (including an increased dose of ICS) during the run-in
Exclusion criteria: Lung disease or additional medical diagnosis other than asthma,
including COPD and chronic bronchitis; established or suspected diagnosis of vocal cord
dysfunction; respiratory tract infection or signiﬁcant asthma exacerbation in previous
four weeks; history of life-threatening asthma requiring treatment with intubation and
mechanical ventilation in previous ﬁve years; hyposensitisation therapy other than an
established maintenance regimen; inability to coordinate use of the delivery devices used
in the study; pregnant
Interventions Intervention Characteristics
ICS + LAMA add-on
• ICS type and dose: beclomethasone dipropionate, 80 mcg twice daily
• LAMA type and dose: tiotropium bromide inhalation powder, 18 mcg once daily
• Inhaler type: tiotropium, SPIRIVA HandiHaler; beclomethasone, QVAR
Inhalation Aerosol
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Peters 2010 (Continued)
• Background medications: all other asthma medications stopped
• Duration of treatment: 14-week treatment period followed by 2-week washout
ICS dose increase
• ICS type and dose: beclomethasone dipropionate, 160 mcg twice daily
• LAMA type and dose: NA
• Inhaler type: beclomethasone, QVAR Inhalation Aerosol
• Background medications: all other asthma medications stopped
• Duration of treatment: 14-week treatment period followed by 2-week washout
Outcomes Continuous:
• Morning PEF L/min
• Evening PEF L/min
• Trough FEV1 (L)
• ACQ
• AQLQ
• Quality of life
• Asthma control
• Lung function
Dichotomous:
• Exacerbations (OCS)
• SAEs (all)
• Exacerbations (ED)
• AEs (all)
• Exacerbations (hospital)
Identiﬁcation Sponsorship source: National Heart, Lung, and Blood Institute
Author name: Vernon M Chinchilli, PhD
Institution: Penn State Hershey College of Medicine
Email: vchinchi@psu.edu
Tel: +1 717-531-4262
Notes Baseline characteristics:
% predicted FEV1 was taken at visit 3 before bronchodilation, the baseline for the ﬁrst
treatment period
Continuous outcomes:
Continuous outcomes were extracted as contrasts to be entered in GIV as this is most
appropriate for cross-over trials
Dichotomous outcomes:
Most patients who had an exacerbation requiringOCSwere also treatedwith intravenous
steroids; one patient received intravenous steroids only and was considered a ’yes’ for this
outcome
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Communication with trial authors: “The
Data Coordinating Centre (DCC) gener-
ated the randomisation scheme via the sta-
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Peters 2010 (Continued)
tistical software package SAS.”
Allocation concealment (selection bias) Low risk Communication with trial authors: “The
network pharmacist constructed
the blinded drug packets according to the
randomisation scheme, and then the drug
packets were shipped to the clinical centres.
The DCC developed a web-based system
in which the study coordinator at a clinical
centre logged into the website whenever an
eligible patient was ready for randomisa-
tion, entered the appropriate information
into the randomisation module, and then
was notiﬁed by the randomisation module
as to the appropriate drug packet for that
eligible patient.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Participants andpersonnel were
blinded to knowledge of which interven-
tion participants received. The clinical trial
register (clinicaltrial.gov) states, “Masking:
Double Blind (Subject, Caregiver, Investi-
gator, Outcomes Assessor).” The primary
manuscript states, “In a three-way, double-
blind, triple-dummy cross-over trial . . .”
and the methods specify that placebo in-
halers were used [for blinding purposes]
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Blinding on ClinicalTrials.gov
described as subject, caregiver, investigator,
outcomes assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Less than 10% of patients in
each group withdrew from the study. Al-
though more patients in the double ICS
groupdroppedout (8%) than in the LAMA
add-on group (4%), the numbers of pa-
tients dropping out due to adverse events
was similar between groups. The difference
arose due to 10 patients withdrawing con-
sent in the double ICS group compared
with only 3 in the LAMA add-on group.
We were provided with the ITTq dataset,
however comparison with the dataset based
on patients who had an event or completed
follow-up showed little or no difference in
the overall results
25Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
(Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Peters 2010 (Continued)
Selective reporting (reporting bias) Low risk Comment: The primary outcome and the
majority of secondary outcomes (i.e. as
speciﬁed in the protocol and ClinicalTri-
als.gov record) are reported for the re-
search hypothesis of interest. The sec-
ondary biomarker outcomes were not re-
ported, other than to state that “levels of
inﬂammatory biomarkers were low at base-
line and thereafter”. However, lack of the
biomarker data in the primary paper do not
inﬂuence assessment of safety or efﬁcacy.
There is a high risk of bias for the outcome
’asthma exacerbations’ as the authors did
not pre-specify the presentation of this out-
come, instead choosing ’number of patients
with an exacerbation’ (rather than time to
ﬁrst exacerbation or total number of exac-
erbations in a treatment group adjusted for
total follow-up for the given intervention)
Other bias High risk HIGH: Quotation: “Although minimal
carryover effects between periods were ob-
served for measures of lung function, an ef-
fect was seen for asthma control days.”
LOW: Quotation: “The company had no
role in the performance of the trial, the
analysis or interpretation of the data, the
preparation of the manuscript, or the deci-
sion to submit the manuscript for publica-
tion.”
ACQ: Asthma Control Questionnaire; AE: adverse events; AQLQ: Asthma Quality of Life Questionnaire; COPD: chronic obstructive
pulmonary disease; ED: emergency department; FEV1: forced expiratory volume in one second; GIV: generic inverse variance; ICS:
inhaled corticosteroids; ITT: intention to treat; LAMA: long-acting muscarinic antagonist; NA: not applicable; OCS: oral corti-
costeroids; PC20: histamine provocative concentration causing a 20% drop in FEV1; PEF: peak expiratory ﬂow; RCT: randomised
controlled trial; SAEs: serious adverse events; SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Beeh 2013 Duration of study too short
Bernstein 2013 Greater than 50% of participants taking LABA
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Casale 2014 Wrong comparator
Corren 2014 Greater than 50% of participants taking LABA
CTRI/2008/091/000306 Wrong comparator
CTRI/2012/08/002915 Wrong comparator
Dahl 2014a Greater than 50% of participants taking LABA
Dahl 2014b Greater than 50% of participants taking LABA
Doherty 2013 Greater than 50% of participants taking LABA
EUCTR2006-003385-34-NL Wrong comparator
Haggart 2004 Wrong intervention
Halpin 2010 Greater than 50% of participants taking LABA
Howaza 2013 Greater than 50% of participants taking LABA
JPRN-UMIN000010352 Wrong comparator
Kerstjens 2012 Greater than 50% of participants taking LABA
NCT00350207 Wrong comparator
NCT00557180 Observational cohort study
NCT00706446 Wrong comparator
NCT01172808 Wrong comparator
NCT01172821 Wrong comparator
NCT01290874 Wrong comparator
NCT01316380 Wrong comparator
NCT01340209 Wrong comparator
NCT01573624 Wrong comparator
NCT01641692 Duration of study too short
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NCT01696214 Wrong comparator
NCT02127697 Wrong comparator
Paggiaro 2013 Wrong comparator
Paggiaro 2014 Wrong comparator
Rajanandh 2014a Wrong comparator
Rajanandh 2014b Wrong comparator
Tashkin 2013 Greater than 50% of participants taking LABA
Vogelberg 2014 Duration of study too short
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D A T A A N D A N A L Y S E S
Comparison 1. ICS + LAMA add-on vs. ICS dose increase
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbations requiring a course
of OCS
1 Odds Ratio (Random, 95% CI) Totals not selected
2 Asthma QoL questionnaire score 1 Mean Difference (Random, 95% CI) Totals not selected
3 SAEs (all cause) 1 Odds Ratio (Random, 95% CI) Totals not selected
4 Exacerbations (hospital) 1 Odds Ratio (Random, 95% CI) Totals not selected
5 Exacerbations (ED) 1 Odds Ratio (Random, 95% CI) Totals not selected
6 FEV1 pre-albuterol (L) 1 Mean Difference (Random, 95% CI) Totals not selected
7 FEV1 post-albuterol (L) 1 Mean Difference (Random, 95% CI) Totals not selected
8 Morning PEF (L/min) 1 Mean Difference (Random, 95% CI) Totals not selected
9 Evening PEF (L/min) 1 Mean Difference (Random, 95% CI) Totals not selected
10 Asthma Control Questionnaire
score
1 Mean Difference (Random, 95% CI) Totals not selected
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As there was only one included study, no meta-analyses, sensitivity analyses or subgroup analyses could be performed.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Adrenal CortexHormones [∗administration & dosage]; Anti-Asthmatic Agents [administration & dosage];
Asthma [∗drug therapy]; Beclomethasone [administration & dosage]; Cross-Over Studies; Muscarinic Antagonists [∗administration &
dosage]; Randomized Controlled Trials as Topic; Tiotropium Bromide [administration & dosage]
MeSH check words
Adult; Humans
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